KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Shares Outstanding (Diluted Average) (2020 - 2026)

Palvella Therapeutics has reported Shares Outstanding (Diluted Average) over the past 3 years, most recently at $73.7 million for Q1 2022.

  • Quarterly Shares Outstanding (Diluted Average) rose 30.93% to $73.7 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $73.7 million through Mar 2022, up 30.93% year-over-year, with the annual reading at $64.5 million for FY2021, 18.48% up from the prior year.
  • Shares Outstanding (Diluted Average) was $73.7 million for Q1 2022 at Palvella Therapeutics, up from $64.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $73.7 million in Q1 2022 and troughed at $53.8 million in Q2 2020.
  • The 3-year median for Shares Outstanding (Diluted Average) is $57.7 million (2021), against an average of $60.5 million.
  • Year-over-year, Shares Outstanding (Diluted Average) rose 9.9% in 2021 and then soared 30.93% in 2022.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $54.5 million in 2020, then grew by 18.48% to $64.5 million in 2021, then grew by 14.2% to $73.7 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Shares Outstanding (Diluted Average) are $73.7 million (Q1 2022), $64.5 million (Q4 2021), and $67.7 million (Q3 2021).